Transparency, And A Mirror: US FDA Advice On COVID-19 Vaccine EUAs Finally Published – Twice
Executive Summary
Everyone but Donald Trump seems happy that the guidance is finally here, with release appearing to be driven by FDA's disclosure of advisory committee materials.
You may also be interested in...
US FDA ‘Bruised’ But Not Broken: Former Commissioners See Agency Intact Amid Transition
Three former commissioners believe FDA has come through the Trump administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?
‘Bruised’ But Not Broken: Ex-Commissioners See FDA Intact Amid Transition
Three former commissioners believe FDA has come through the Trump Administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?
‘The Gruber Moment’: How CBER Got The Answers It Wanted On COVID Vaccine Guidance
As US FDA recovers from aducanumab and looks towards an advisory committee on Pfizer’s COVID vaccine, it’s worth reflecting on how Office of Vaccine Research & Review Director Marion Gruber created positive turning points for the agency during a general discussion of vaccine approval standards at the VRBPAC.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: